2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 4 filers reported holding 2SEVENTY BIO INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,000 | -44.4% | 10,353 | +44.8% | 0.00% | – |
| Q2 2023 | $72,000 | +80.0% | 7,148 | +77.6% | 0.00% | – |
| Q1 2023 | $40,000 | -31.0% | 4,025 | -34.6% | 0.00% | – |
| Q4 2022 | $58,000 | -12.1% | 6,159 | +39.0% | 0.00% | – |
| Q3 2022 | $66,000 | +43.5% | 4,430 | +25.9% | 0.00% | – |
| Q2 2022 | $46,000 | -45.2% | 3,520 | -28.2% | 0.00% | – |
| Q1 2022 | $84,000 | -58.6% | 4,905 | -37.9% | 0.00% | – |
| Q4 2021 | $203,000 | – | 7,899 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 4,890,706 | $49,493,945 | 6.81% |
| CHI Advisors LLC | 852,007 | $8,622,311 | 2.62% |
| Casdin Capital, LLC | 2,023,913 | $20,482,000 | 1.79% |
| Newtyn Management, LLC | 737,744 | $7,465,969 | 1.76% |
| Bain Capital Life Sciences Investors, LLC | 1,408,901 | $14,258,078 | 1.47% |
| DAFNA Capital Management LLC | 496,416 | $5,023,730 | 1.37% |
| AlphaCentric Advisors LLC | 180,000 | $1,821,600 | 1.01% |
| SECTORAL ASSET MANAGEMENT INC | 462,485 | $4,680,348 | 0.78% |
| CLOUGH CAPITAL PARTNERS L P | 529,110 | $5,354,593 | 0.54% |
| Bleichroeder LP | 255,230 | $2,582,928 | 0.52% |